An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 conditions characterized by inflammation and fibrosis of the lung interstitium, leading to progressive dyspnea and cough.
Etiology and Classification
ILDs can be idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF). Other forms include nonspecific interstitial pneumonia and sarcoidosis.
Clinical Manifestations and Diagnosis
Patients typically present with progressive dyspnea and dry cough. Physical examination may reveal crackles and clubbing. High-resolution CT is the gold standard for diagnosis. Pulmonary function tests show a restrictive pattern and reduced diffusion capacity.
Treatment and Prognosis
Treatment is largely supportive, including oxygen therapy and pulmonary rehabilitation. Antifibrotic drugs like pirfenidone and nintedanib are approved for IPF. Prognosis varies widely, with IPF having a median survival of 2-3 years post-diagnosis.
Conclusion
ILDs are complex disorders requiring a thorough understanding for effective management. Further research is needed to develop more effective treatments and improve patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study
2.
Study shows virtual reality headsets may help ease cancer pain
3.
Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer
4.
Spouses of Cancer Patients May Be at Increased Risk of Suicide
5.
Study finds 81% of cancer cures touted by TikTok videos are fake
1.
Personalized Survivorship Navigation in Precision Cancer Care
2.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
3.
Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy
4.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
5.
Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Nutrition Can Support Patients During Cancer Care
2.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
5.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge